AnovoRx

Overview

AnovoRx is a TPG Growth-backed, Memphis-based rare-disease specialty pharmacy that combines 3PL, patient support services, and exclusive specialty dispensing for orphan and ultra-orphan launches. The platform operates as three integrated subsidiaries so that distribution, coverage navigation, financial assistance, injection training, and dispensing flow under one manufacturer contract.

AnovoRx is not a national broad-network specialty pharmacy and not a PBM-owned channel. The fit is rare-disease launches where a conventional broad pharmacy network would dilute service quality; documented partners include Stealth BioTherapeutics (FORZINITY, Barth syndrome) and Eton Pharmaceuticals (HEMANGEOL, Increlex, ALKINDI SPRINKLE, generic carglumic acid).

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, AnovoRx is evaluated as TPG Growth-backed, Memphis-based rare-disease specialty pharmacy that combines 3PL, patient support services, and exclusive specialty dispensing for orphan and ultra-orphan launches.

Capability	Buyer should compare	AnovoRx readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Core for rare disease. Exclusive and limited-distribution dispensing for orphan and complex chronic conditions; documented exclusive U.S. roles on FORZINITY and multiple Eton products.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Core coverage workflow. Insurance navigation, PA, appeals, copay, and patient assistance built into the patient-support layer (e.g., Mito Assist for FORZINITY).
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Core for high-touch model. At-home subcutaneous injection training, caregiver coordination, and ongoing prescriber communication are public examples; validate by therapy.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	Confirm complex-product handling in the RFP. Cold-chain and REMS handling are not the lead public claim; confirm per-product scope and supporting infrastructure.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Documented through manufacturer programs. AnovoRx reports patient status and milestones to launch partners; specify exact fields, cadence, and dashboarding in the SOW.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Adjacent. Focus is direct-to-patient and prescriber coordination for orphan products; broad infusion and health-system coordination are not the public model.

Buyer Fit

• Use-case fit: A biotech launching an orphan or ultra-orphan therapy that wants one vendor for 3PL, patient support, financial assistance, injection training, and exclusive dispensing rather than stitching together hub plus SP plus 3PL.
• Best-fit buyers: Rare-disease biotech access and launch teams, including repeat-partner programs like Stealth Mito Assist and the multi-product Eton portfolio.
• Less ideal fit: Products that need payer-routing leverage, broad LDD network presence, or enterprise-scale pharmacy footprint; PBM-owned specialty pharmacies are the comparison set there.
• Commercial fit: Pricing is custom / RFP-led; assume a launch-specific scope with SLAs across distribution, patient services, and dispensing.
• Profile signal: Repeat manufacturer relationships across Stealth (FORZINITY) and Eton (Increlex, ALKINDI SPRINKLE, HEMANGEOL, carglumic acid) plus a 2026 CEO appointment of Steve Fitzpatrick, a former Accredo operator and specialty-services board member.
• Contracting diligence: Confirm which services are delivered directly by AnovoRx versus subcontracted, how patient-status data flows to the manufacturer, and how payer-mandated transfers to a different specialty pharmacy are governed.

Differentiators

• Integrated 3PL + hub + SP model: Distribution, patient services, and specialty dispensing sit inside one AnovoRx operating model, reducing the number of vendors and contracts at launch.
• Rare-disease portfolio focus: Public launches skew orphan and ultra-orphan, not high-volume retail-style specialty categories.
• Independent ownership: AnovoRx is TPG Growth-backed and not owned by a PBM, payer, wholesaler, or pharmacy chain.
• Eton repeat-partner pattern: Multiple Eton products under exclusive distribution indicates an institutional manufacturer relationship rather than a one-off award.
• Senior operating leadership: Steve Fitzpatrick (former Accredo) appointed CEO in March 2026, signaling investment in scaled execution discipline.

RFP Questions

• Which services in the proposed program are delivered directly by AnovoRx versus subcontracted, and to whom?
• How will AnovoRx report patient status, BI / BV, PA, appeal outcomes, dispense milestones, and time-to-first-fill to the manufacturer?
• What evidence can AnovoRx show for time-to-first-fill, abandonment reduction, adherence, and patient satisfaction on comparable rare-disease programs?
• How are the 3PL, patient services, and specialty pharmacy workflows governed when a single patient moves from access support to first shipment?
• Which payer networks, REMS authorizations, and state licenses are already in place for the product class in scope?
• How are payer-mandated transfers to a different specialty pharmacy handled, and what data continues to flow back to the manufacturer in that case?
• What references from Stealth, Eton, or comparable rare-disease manufacturers can AnovoRx provide for diligence calls?

Recent Activity

• 2026-05 - Eton relaunched HEMANGEOL with Anovo Specialty Pharmacy as the exclusive distribution partner under the Eton Cares support model.
• 2026-03 - AnovoRx appointed Steve Fitzpatrick CEO, adding senior Accredo and specialty-services operating experience.
• 2025-10 - Stealth BioTherapeutics selected AnovoRx as exclusive U.S. commercial distribution partner for FORZINITY (elamipretide) and the Mito Assist patient-support program.
• 2024-12 - Eton closed the Increlex (mecasermin) acquisition and named AnovoRx as the exclusive U.S. specialty pharmacy.
• 2022-01 - TPG Growth made a significant minority investment in AnovoRx.